Clinical Trials in Humble, Texas
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Type 1 DiabetesType 1 Diabetes MellitusType 1 Diabetes Mellitis+7 more
COUR Pharmaceutical Development Company, Inc.72 enrolled31 locationsNCT06783309
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca990 enrolled297 locationsNCT06883305
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled564 locationsNCT07037459
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled229 locationsNCT07181109
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled753 locationsNCT06742723
Recruiting
Not Applicable
Pivotal Study of the Velocity™ pAVF System
Chronic Kidney DiseaseEnd Stage Renal Disease (ESRD)Hemodialysis Access+1 more
Venova Medical126 enrolled10 locationsNCT07153939
Recruiting
Not Applicable
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPDSmokingTobacco Use
Philip Morris Products S.A.290 enrolled111 locationsNCT07108166
Recruiting
Phase 2
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Basal Cell Carcinoma
Stamford Pharmaceuticals, Inc.80 enrolled10 locationsNCT06344052